Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.
FDA panel vote on COVID-19 vaccines for young children; new drug approved to treat alopecia; Paxlovid tested in standard risk individuals.
The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.
Ukoniq has been withdrawn by the FDA; Drug pipeline news in asthma, dermatology and oncology; And there’s positive results for a novel postpartum depression treatment.
The latest guidance for COVID-19 treatment Paxlovid following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; COVID-19 vaccine efficacy update for those aged under 5; And the latest on Monkeypox.
The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review.
Treatment approved for hospitalized COVID patients; Update on Varenicline; Limits have been set for the Janssen vaccine; weekly dose podcast!
USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Five Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House releases a plan to tackle the overdose epidemic.
This week: The sabizabulin trial in COVID-19 is halted; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Greater diversity called for in Clinical Trials; Myopericarditis risk compared for COVID-19 vaccines vs other vaccines; And survey results of unvaccinated attitudes following FDA approval.
A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHevbrio hepatitis B vaccine now available; And the FDA update a safety communication regard the risk of thyroid dysfunction in infants following the use of contrast…
Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID-19 tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.
Subscribe: Apple Podcasts | Deezer | Spotify | Stitcher In this week’s special episode of The Weekly Dose Podcast we interview Dr Tobias Janowitz, a medical oncologist, assistant professor at the Cold Spring Harbor Laboratories and adjunct professor at the Feinstein Institutes. Dr Janowitz was part of a team that recently conducted a phase 2…
A new injection is approved for opioid overdoses; The Advisory Committee on Immunization Practices releases vaccine schedules; The FDA provides a list of approved COVID-19 tests; A trial of an investigational spontaneous urticaria treatment is stopped; And the first condom is authorized for anal intercourse.
This week: in COVID related news, a heartburn medication shows benefits; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issues an alert regarding ketamine compounding.
This week: millions of courses of a COVID-19 oral antiviral was provided to the US government for distribution throughout the country; There’s a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF.
This week: The approval of a second COVID-19 vaccine; Pfizer and BioNTech submit for Emergency Use of their vaccine for children under 5; Pfizer also stop development on a potential drug treatment to reduce cardiovascular risk and severe hypertriglyceridemia; And a HIV drug gets new dosing option.
This week: Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; Parsaclisib’s NDA withdrawn; New data produces a reconsideration for Pepaxto withdrawal; And there’s a new treatment approval for unresectable or metastatic uveal melanoma.
This week, two new approvals for atopic dermatitis; Warnings around counterfeit HIV treatments; Some US indications for Zydelig are withdrawn; CDC pediatric flu vaccine study results; And an FDA warning against certain COVID-19 antibody tests.
This week news of a new treatment for insomnia; The FDA comment on magnesium hypertension claims; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycles in relation to COVID vaccines; And experts have their say on the best diets for 2022.
Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.